Dr. TANG Weikun
Mr. ZHOU Chao
Mr. YANG Guang
Dr. TANG Weikun, aged 36, joined Grand Pharma (China) Co., Ltd. (a major subsidiary of the Group, Grand Pharma (China)) in 2012 and worked for several companies of the Group. He has been the assistant of the president of Grand Pharma (China) since April 2019, and was appointed as the president of Grand Pharma (China) with effect from 1 June 2021. Dr. TANG has overall responsible for the operation of Grand Pharma (China). Dr. TANG completed his life science and technology undergraduate education at Wuhan University in 2007, and obtained his doctoral degree in microbiology from the College of Life Sciences, Wuhan University in 2012.
Zhou Chao, has joined the Yuanda Pharmaceutical Group since June 2019. Since June 2021, Mr Zhou has become the chief executive officer of the Group and one of the directors of several associated companies of the Group. Mr Zhou has also been responsible for the general internal management of the Group. Before joining our Group, Mr Zhou was the legal manager, senior legal manager and business director of Legal Security Management Department of China Grand Enterprises (which is a major shareholder of our Group). Now, Mr Zhou holds directorships in a number of domestic and overseas companies of the Group. Mr Zhou has headed and participated in several large-scale merger and acquisition projects both locally and overseas, and introduced a variety of products for our Group. In 2011, Mr Zhou graduated from Ocean University of China with a Bachelor's Degree in Laws and subsequently obtained a Master's Degree in International Economic Law from the University of International Business and Economics.
Mr. Yang Guang has over 20 years’ experience in business development. He has been the general manager of the investment management headquarters (formerly known as investment development headquarters) of China Grand Enterprises Incorporation (a substantial shareholder of the Company) since 2019. Mr. Yang obtained his bachelor degree in pharmaceutical preparations from the China Pharmaceutical University in 1996. He also obtained a master degree in bio-pharmacy engineering from the Tianjin University in 2007, and a master degree of business administration from the China Europe International Business School in 2013.
Ms. SU Caiyun
Dr. Xing Li Na
Mr. HU Yebi
Dr. PEI Geng
Ms. SU Caiyun was appointed independent non-executive director of the Company in March 2005. Ms So is a fellow member of the Association of Chartered Certified Accountants and a practicing member of the Hong Kong Institute of Certified Public Accountants. She is a partner of an accounting firm.
Dr. Xing Li Na joined China Grand Enterprises, INC. in November 2023 as senior business director of the pharmaceutical strategic management headquarters. She has many years of experience in review work at the Medical Device Technical Review Center of the State Food and Drug Administration, and served as deputy director of preclinical safety research for new drugs at BeiGene (Beijing) Biotechnology Co., Ltd. Dr. Xing obtained a postgraduate degree in medicine from Peking University School of Medicine in 2012.
Mr. Hu Yebi, received his Master of Business Administration from Netherlands International Institute for Management in the Netherlands and a Postgraduate Diploma in Management Engineering from Beijing Institute of Technology in Beijing, the PRC. Mr. Hu has more than twenty years of experience in securities and financial services, mergers and acquisitions and corporate finance. Mr. Hu is the founder and chairman of Vision Finance Group Limited. Mr. Hu is currently a non-executive director of Beijing Sports and Entertainment Industry Group Limited (stock code: 1803) and was an executive director of Tai United Holdings Limited (stock code: 718), Hua Lien International (Holding) Company Limited (stock code: 969), Beijing Enterprises Medical and Health Industry Limited (stock code: 2389) and Beijing Properties (Holdings) Limited (stock code: 925), but already resigned in October 2016, July 2017, October 2018 and November 2018 respectively. All these companies are listed on The Stock Exchange of Hong Kong Limited.
Dr. Pei Geng is currently working in Multiway Trading Intl., USA and its Beijing branch, with TDR company in the USA. Dr. Pei has specialized in the areas of neurosurgery and neuroscience for over 20 years. Dr. Pei holds a bachelor degree in Medicine and became a clinician after graduation from Capital Medical University, Beijing, China. Dr. Pei also holds a licentiate degree in Medical Sciences from Uppsala University of Medicine, Sweden and a PhD degree in neuroscience from University of Würzburg, Germany.
Memorandum of Association and Bye-Laws
Add Time: May 2012
Terms of Reference of Audit Committee
Add Time: March 2016
Terms of Reference of Nomination Committee
Add Time: March 2012
Terms of Reference of Remuneration Committee
Add Time: March 2012
Procedures Shareholders Use to Propose a Person for Election as a Director
Add Time: March 2012
